SMYD2 and chronic kidney disease: The application of AZ505 alleviates polycystic kidney fibrosis and inhibits the proliferative activation of renal mesenchymal fibroblasts as well as epithelial mesenchymal transition (EMT), suggesting that SMYD2 may be a potential therapeutic target for CKD.